PET Imaging in Preclinical Anti-Aβ Drug Development
| Autor: | Stina Syvänen, Silvio R. Meier, Sahar Roshanbin, Mengfei Xiong, Rebecca Faresjö, Tobias Gustavsson, Gillian Bonvicini, Eva Schlein, Ximena Aguilar, Ulrika Julku, Jonas Eriksson, Dag Sehlin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Pharmacology
Amyloid Amyloid beta-Peptides Neurologi Organic Chemistry Pharmaceutical Science Brain Alzheimer's disease Farmaceutiska vetenskaper drug development amyloid-beta animal models Pharmaceutical Sciences Drug Development Neurology Alzheimer Disease Positron-Emission Tomography Molecular Medicine Animals Positron Emission Tomography (PET) Pharmacology (medical) Biotechnology |
| Popis: | Positron emission tomography (PET), a medical imaging technique allowing for studies of the living human brain, has gained an important role in clinical trials of novel drugs against Alzheimer’s disease (AD). For example, PET data contributed to the conditional approval in 2021 of aducanumab, an antibody directed towards amyloid-beta (Aβ) aggregates, by showing a dose-dependent reduction in brain amyloid after treatment. In parallel to clinical studies, preclinical studies in animal models of Aβ pathology may also benefit from PET as a tool to detect target engagement and treatment effects of anti-Aβ drug candidates. PET is associated with a high level of translatability between species as similar, non-invasive protocols allow for longitudinal rather than cross-sectional studies and can be used both in a preclinical and clinical setting. This review focuses on the use of preclinical PET imaging in genetically modified animals that express human Aβ, and its present and potential future role in the development of drugs aimed at reducing brain Aβ levels as a therapeutic strategy to halt disease progression in AD. Title in Web of Science: PET Imaging in Preclinical Anti-A beta Drug Development |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|